FDA Reviewers Say J&J, Bayer Blood Thinner Should Be Rejected
Staff scientists at the Food and Drug Administration recommend that the agency reject Xarelto, a new blood thinner being developed by Bayer and Johnson & Johnson.The review, which can be found here, is a huge blow to the drug giants. Analysts largely expected that Xarelto would generate peak sales of $1 billion or more.An FDA disclaimer states that the conclusions of the report “do not necessarily represent the final position of the individual reviewers,” not to mention the agency itself. …